hello world
Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.
Stocks in play: Microbix Biosystems Inc.
Is presenting results of its use of Microbix Quality Assessment Products for accreditation of clinical labs for conducting molecular tests for antimicrobial-resistant strains of M. genitalium, a common sexually-transmitted infection. Microbix Biosystems Inc. shares T.MBX are trading unchanged at $0.34.
